

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation of the mixture CEFTIN FOR ORAL SUSPENSION

Registration number -

Synonyms CEFTIN SUSPENSION 125 MG/5 ML * CEFTIN SUSPENSION 250 MG/5 ML * CEFTIN ORAL SUSPENSION * CEFTUM ORAL SUSPENSION 125 MG/5 ML * CEFUROX ORAL SUSPENSION * CEFCEP ORAL SUSPENSION * ELOBACT ORAL SUSPENSION * ELOBACT GRANULES * ELOBACT 125 MG DOSIERBRIEFE * ZINADOL ORAL SUSPENSION * ZINAT SUSPENSION * ZINNAT SUSPENSION SACHET 125 MG * ZINNAT SUSPENSION 25 MG/ML * ZINACEF SUSPENSION * ZIPOS ORAL SUSPENSION * ZOREF ORAL SUSPENSION * NDC NO 0173-0740-00 * NDC NO 0173-0741-00 * NDC NO 0173-0741-10 * CEFUROXIME AXETIL, FORMULATED PRODUCT

Issue date 30-September-2013

Version number 14

Revision date 30-September-2013

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.

Uses advised against No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information (normal business hours): +44-20-8047-5000
Email Address: msds@gsk.com
Website: www.gsk.com

1.4. Emergency telephone number

TRANSPORT EMERGENCIES::
UK In-country toll call: +(44)-870-8200418
International toll call: +1 703 527 3887
available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

The mixture has been assessed and/or tested for its physical, health and environmental hazards and the following classification applies.

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Supplemental label information Not applicable.

2.3. Other hazards

Assume that this material is capable of sustaining combustion.
Assume that this material is capable of producing a dust explosion if ignited as a dust cloud.
Assume that this material is capable of being ignited by an electrostatic discharge.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
May cause an allergic skin reaction.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

General information

Chemical name	%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
Sucrose	60 - < 70	57-50-1 200-334-9	-	-	
Classification:	DSD: - CLP: -				
Stearic acid	20 - < 30	57-11-4 200-313-4	-	-	
Classification:	DSD: - CLP: -				
CEFUROXIME AXETIL	3.5 - < 7.5	64544-07-6 -	-	-	
Classification:	DSD: R42/43 CLP: Skin Sens. 1;H317, Resp. Sens. 1;H334				
TUTTI FRUTTI	1 - < 3	Unassigned -	-	-	
Classification:	DSD: - CLP: -				
ASPARTAME	< 1	22839-47-0 245-261-3	-	-	
Classification:	DSD: - CLP: -				
XANTHAN GUM	< 0.1	11138-66-2 234-394-2	-	-	
Classification:	DSD: - CLP: -				

Other components below reportable levels 1 - < 3

CLP: Regulation No. 1272/2008.

DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance.

PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information

Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Wash contaminated clothing before reuse.

4.1. Description of first aid measures

Inhalation

If dust from the material is inhaled, remove the affected person immediately to fresh air. Oxygen or artificial respiration if needed. Do not use mouth-to-mouth method if victim inhaled the substance. Induce artificial respiration with the aid of a pocket mask equipped with a one-way valve or other proper respiratory medical device. If experiencing respiratory symptoms: Call a POISON CENTRE or doctor/physician.

Skin contact

Wash off with soap and plenty of water. If skin irritation or rash occurs: Get medical advice/attention. For minor skin contact, avoid spreading material on unaffected skin.

Eye contact

Rinse with water. Get medical attention if irritation develops and persists.

Ingestion

Get medical attention if symptoms occur. Rinse mouth.

4.2. Most important symptoms and effects, both acute and delayed	May cause allergic skin reaction. May cause allergic respiratory reaction.
4.3. Indication of any immediate medical attention and special treatment needed	Provide general supportive measures and treat symptomatically. Symptoms may be delayed.

SECTION 5: Firefighting measures

General fire hazards	Assume that this material is capable of sustaining combustion.
5.1. Extinguishing media	
Suitable extinguishing media	Alcohol resistant foam. Water spray. Water fog. Dry chemical powder.
Unsuitable extinguishing media	Carbon dioxide (CO ₂).
5.2. Special hazards arising from the substance or mixture	During fire, gases hazardous to health may be formed.
5.3. Advice for firefighters	
Special protective equipment for firefighters	Self-contained breathing apparatus and full protective clothing must be worn in case of fire.
Special fire fighting procedures	In the event of fire, cool tanks with water spray.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures	
For non-emergency personnel	Keep unnecessary personnel away. Wear a dust mask if dust is generated above exposure limits. Avoid inhalation of dust from the spilled material. For personal protection, see section 8.
For emergency responders	Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the MSDS.
6.2. Environmental precautions	Avoid discharge into drains, water courses or onto the ground.
6.3. Methods and material for containment and cleaning up	Minimise dust generation and accumulation. If sweeping of a contaminated area is necessary use a dust suppressant agent which does not react with the product. Sweep up or vacuum up spillage and collect in suitable container for disposal. Collect dust using a vacuum cleaner equipped with HEPA filter. Following product recovery, flush area with water.
6.4. Reference to other sections	For personal protection, see section 8. For waste disposal, see section 13.

SECTION 7: Handling and storage

7.1. Precautions for safe handling	Minimise dust generation and accumulation. Provide appropriate exhaust ventilation at places where dust is formed. Avoid breathing dust. Avoid contact with skin and eyes. Avoid prolonged exposure. In case of insufficient ventilation, wear suitable respiratory equipment. Practice good housekeeping.
7.2. Conditions for safe storage, including any incompatibilities	Store in original tightly closed container. Store in a well-ventilated place. Guard against dust accumulation of this material. Store away from incompatible materials (see Section 10 of the MSDS).
7.3. Specific end use(s)	Medicinal Product

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK Components	Type	Value	Note
ASPARTAME (CAS 22839-47-0)	8 HR TWA	5000 mcg/m ³	
CEFUROXIME AXETIL (CAS 64544-07-6)	OHC	1	
	15 MIN STEL	100 mcg/m ³	
	OHC	3 3	SKIN SENSITISER RESPIRATORY SENSITISER
TUTTI FRUTTI (CAS Unassigned)	8 HR TWA	5000 mcg/m ³	
XANTHAN GUM (CAS 11138-66-2)	OHC	1	
	OHC	1	

UK. EH40 Workplace Exposure Limits (WELs)		
Components	Type	Value
Sucrose (CAS 57-50-1)	STEL	20 mg/m3
	TWA	10 mg/m3
Recommended monitoring procedures	Follow standard monitoring procedures.	
Derived No Effect Level (DNEL)	Not available.	
Predicted no effect concentrations (PNECs)	Not available.	
8.2. Exposure controls		
Appropriate engineering controls	An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment.	
Individual protection measures, such as personal protective equipment		
General information	Personal protection equipment should be chosen according to the CEN standards and in discussion with the supplier of the personal protective equipment. Follow all local regulations if personal protective equipment (PPE) is used in the workplace.	
Eye/face protection	Not normally needed.	
Skin protection		
- Hand protection	The choice of an appropriate glove does not only depend on its material but also on other quality features and is different from one producer to the other. Glove selection must take into account any solvents and other hazards present. Select suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time).	
- Other	Not normally needed.	
Respiratory protection	No personal respiratory protective equipment normally required.	
Thermal hazards	Wear appropriate thermal protective clothing, when necessary.	
Hygiene measures	An occupational/industrial hygiene monitoring method has been developed for this material. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional.	
Environmental exposure controls		
Hazard guidance and control recommendations	Not available.	

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state	Solid.
Form	Powder.
Colour	Not available.
Odour	Not available.
Odour threshold	Not available.
pH	Not available.
Melting point/freezing point	Not available.
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.
Upper/lower flammability or explosive limits	
Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Vapour pressure	Not available.
Vapour density	Not available.
Relative density	Not available.
Solubility(ies)	Not available.

Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Explosive properties	Not available.
Oxidizing properties	Not available.
9.2. Other information	No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
10.2. Chemical stability	Material is stable under normal conditions.
10.3. Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
10.4. Conditions to avoid	Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Contact with incompatible materials.
10.5. Incompatible materials	Strong oxidising agents.
10.6. Hazardous decomposition products	Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

SECTION 11: Toxicological information

General information	Occupational exposure to the substance or mixture may cause adverse effects. This material is an antibiotic, a cephalosporin.
----------------------------	---

Information on likely routes of exposure

Ingestion	Not expected to be toxic following ingestion.
Inhalation	May cause allergy or asthma symptoms or breathing difficulties if inhaled. Inhalation of dusts may cause respiratory irritation.
Skin contact	May cause an allergic skin reaction.
Eye contact	May be irritating to eyes.
Symptoms	Not available.

11.1. Information on toxicological effects

Acute toxicity	May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause allergic skin reaction.
-----------------------	--

Components	Species	Test results
CEFUROXIME AXETIL (CAS 64544-07-6)		
Acute		
<i>Oral</i>		
LD50	Rat	> 2000 g/kg
Stearic acid (CAS 57-11-4)		
Acute		
<i>Oral</i>		
LD50	Rat	> 5000 mg/kg
XANTHAN GUM (CAS 11138-66-2)		
Acute		
<i>Inhalation</i>		
LC50	Rat	> 21 mg/l, 1 hour exposure
<i>Oral</i>		
LD50	Rat	> 5000 mg/kg

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation	Based on available data, the classification criteria are not met.
----------------------------------	---

Corrosivity

CEFUROXIME AXETIL	Read across Result: Mild irritant Species: Human
-------------------	--

Serious eye damage/eye irritation	Dust in the eyes will cause irritation.
--	---

Eye CEFUROXIME AXETIL	Read across Result: Mild irritant Species: Human
Respiratory sensitisation CEFUROXIME AXETIL	May cause allergy or asthma symptoms or breathing difficulties if inhaled. Read Across Result: positive Species: Human
Skin sensitisation Sensitisation CEFUROXIME AXETIL	May cause an allergic skin reaction. Read Across Result: positive Species: Human
Germ cell mutagenicity Germ cell mutagenicity Mutagenicity CEFUROXIME AXETIL	Based on available data, the classification criteria are not met. Ames Result: negative Chromosomal Aberration Assay In Vitro Result: positive Mouse Lymphoma Cell Assay Result: negative in vitro micronucleus assay Result: negative Species: Rat
Carcinogenicity	Due to lack of data the classification is not possible.
Reproductive toxicity	Based on available data, the classification criteria are not met.
Reproductive toxicity Reproductivity CEFUROXIME AXETIL	Embryofetal Development Result: No known effects Species: Human
Specific target organ toxicity - single exposure	Due to lack of data the classification is not possible.
Specific target organ toxicity - repeated exposure	Due to lack of data the classification is not possible.
Aspiration hazard	Due to lack of data the classification is not possible.
Mixture versus substance information	Not available.
Other information	This material is a cephalosporin antibiotic.

SECTION 12: Ecological information

12.1. Toxicity No information is available about the potential of this product to produce adverse environmental effects.

Components		Species	Test results
CEFUROXIME AXETIL (CAS 64544-07-6)			
Aquatic			
Acute			
Activated Sludge Respiration	IC50	Residential sludge	> 100 mg/l, 3 hours, OECD 209
Algae	EC50	Green algae (Selenastrum capricornutum)	> 91 mg/l, 72 hours, Static test, OECD 201
	NOEC	Green algae (Selenastrum capricornutum)	91 mg/l, 72 hours, Static test
Crustacea	EC50	Water flea (Daphnia magna)	> 1000 mg/l, 48 hours, Static test, OECD 202
	NOEC	Water flea (Daphnia magna)	> 1000 mg/l, 48 hours, Static test
Fish	EC50	Rainbow trout (Adult Oncorhyncus mykiss)	> 120 mg/l, 96 hours, Static test, OECD 203
	NOEC	Rainbow trout (Adult Oncorhyncus mykiss)	120 mg/l, 96 hours, Static test
Microtox	MIC	Azotobacter beijerinckii	0.2 mg/l

Components		Species	Test results
Other	MIC	Aspergillus niger	> 1 mg/l
		Nostoc commune	0.2 mg/l
		Pseudomonas aeruginosa	> 1 mg/l
		Trichoderma harzianum	> 1 mg/l
Stearic acid (CAS 57-11-4)			
Aquatic			
Acute			
Fish	EC50	Orange-red killfish (Adult Oryzias latipes)	125 mg/l, 96 hours
Microtox	EC50	Microtox	12 mg/l, 15 minutes
XANTHAN GUM (CAS 11138-66-2)			
Aquatic			
Acute			
Fish	EC50	Rainbow trout (Adult Oncorhyncus mykiss)	420 mg/l, 96 hours, Static test

* Estimates for product may be based on additional component data not shown.

12.2. Persistence and degradability

Persistence and degradability

Photolysis

Half-life (Photolysis-atmospheric)

Stearic acid 17 Hours Estimated

UV/visible spectrum wavelength

CEFUROXIME AXETIL 290 nm

Stearic acid 210 nm

Hydrolysis

Half-life (Hydrolysis-acidic)

CEFUROXIME AXETIL 299 Hours

Half-life (Hydrolysis-basic)

ASPARTAME < 1 Days Measured

CEFUROXIME AXETIL 1.05 Hours

Half-life (Hydrolysis-neutral)

CEFUROXIME AXETIL 30.2 Hours

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

CEFUROXIME AXETIL 74 %, < 1 day Modified Zahn-Wellens, primary biodegradation, loss of parent., Activated sludge

Stearic acid 77 %, 28 days BOD

Sucrose 69 % BOD5

Percent degradation (Aerobic biodegradation-ready)

ASPARTAME 60 - 90 %, 5 days

CEFUROXIME AXETIL 28 %, 28 days Modified Sturm test.

42 %, 64 days Modified Sturm test.

Stearic acid 95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

CEFUROXIME AXETIL 42.8 - 80 %, 64 days

Stearic acid 50 %, 13 days

12.3. Bioaccumulative potential

Partition coefficient

n-octanol/water (log Kow)

CEFUROXIME AXETIL 0.8 - 1.24

Stearic acid 8.23

8.42

Sucrose -3

Bioconcentration factor (BCF)

ASPARTAME 1 Estimated

Stearic acid > 9999 Estimated

12.4. Mobility in soil

Adsorption

Soil/sediment sorption - log K_{oc}

ASPARTAME	1.78 Estimated
CEFUROXIME AXETIL	1.09 - 1.19
Stearic acid	5.86 Estimated

Mobility in general

Volatility

Henry's law

ASPARTAME	< 0 atm m ³ /mol Estimated
CEFUROXIME AXETIL	0 atm m ³ /mol, 25 C Estimated
Stearic acid	0.000051 Estimated
Sucrose	< 0 atm m ³ /mol Estimated

12.5. Results of PBT and vPvB assessment Not available.

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste	Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).
Contaminated packaging	Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.
EU waste code	The Waste code should be assigned in discussion between the user, the producer and the waste disposal company.
Disposal methods/information	Collect and reclaim or dispose in sealed containers at licensed waste disposal site.
Special precautions	Dispose in accordance with all applicable regulations.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(1) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations

The product is classified and labelled in accordance with EC directives or respective national laws. This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

National regulations

Young people under 18 years old are not allow to work with this product according to the EU Directive 94/33/EC on the protection of young people at work. Follow national regulation for work with chemical agents.

15.2. Chemical safety assessment

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations

Not available.

References

GSK Hazard Determination

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.

Full text of any statements or R-phrases and H-statements under Sections 2 to 15

R42/43 May cause sensitization by inhalation and skin contact.
H317 May cause an allergic skin reaction.
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Revision information

Product and Company Identification: Business Units
Composition / Information on Ingredients: Ingredients
Physical & Chemical Properties:
Transport Information: Agency Name and Packaging Type/Transport Mode Selection
Regulatory Information: United States
GHS: Classification

Training information

Follow training instructions when handling this material.

Disclaimer

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.